131 completed. 131 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 131 | Completed 131 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intralesional Bleomycin Sclerotherapy for Low-Flow Vascular Malformations of the Head and Neck Bleomycin (Bleocel 15) - Vascular Malformations, Venous Malformation | Phase 4 | Completed | University Of Anbar | 20 | 2025-08-25 | 2026-07-27 |
| The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery Bridion 200 MG in 2 ML Injection, Pyridostigmine Bromide 5 MG/ML - Emergence Delirium, Strabismus | Phase 4 | Completed | Konkuk University Medical Center | 76 | 2023-12-01 | 2026-07-15 |
| A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy Mogamulizumab - Cutaneous T-Cell Lymphoma | Phase 4 | Completed | Kyowa Kirin China Pharmaceutical Co., Ltd. | 23 | 2023-05-29 | 2026-09-09 |
| A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia inotuzumab ozogamicin - Acute Lymphoblastic Leukemia | Phase 4 | Completed | Pfizer | 44 | 2023-02-24 | 2025-12-03 |
| A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients Emapalumab-Lzsg 5 MG/ML [Gamifant] - Primary Hemophagocytic Lymphohistiocytosis | Phase 4 | Completed | Swedish Orphan Biovitrum | 13 | 2023-02-03 | 2026-08-26 |
| A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma Brentuximab vedotin - T-Cell Lymphoma | Phase 4 | Completed | Takeda | 10 | 2022-11-28 | 2025-09-18 |
| Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency Guilu Erxian Oral Liquid, Wuzi Yanzong oral liquid - Mild and Moderate Oligozoospermia Asthenospermia or Oligoasthenospermia and the Syndrome Differentiation Type is Shen (Kidney) Essence Deficiency | Phase 4 | Completed | DongE E Jiao Coporation Limited | 360 | 2022-10-08 | 2025-12-08 |
| Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome Pegloticase, Rasburicase - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 4 | Completed | M.D. Anderson Cancer Center | 10 | 2022-04-05 | 2026-05-06 |
| Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting Telemedicine Visit, Vital sign measurements, Out-Patient Clinic Visit - Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 4 | Completed | Vanderbilt-Ingram Cancer Center | 25 | 2021-12-02 | 2025-03-27 |
| Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Administration of Albendazole on Day 1, Administration of Ivermectin on Day 1, Administration of Azithromycin on Day 1 - Trachoma, Lymphatic Filariases | Phase 4 | Completed | London School of Hygiene and Tropical Medicine | 13511 | 2021-12-01 | 2022-08-19 |
| Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma Acalabrutinib capsule - Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma | Phase 4 | Completed | AstraZeneca | 103 | 2021-07-14 | 2024-11-22 |
| Nalbuphine Versus Ketamine for Prevention of Emergence Agitation After Sevoflurane in Children Undergoing Tonsillectomy Nalbuphine Injection, Ketamine, Saline - Pediatric ALL, Pediatric Anesthesia | Phase 4 | Completed | Ain Shams University | 90 | 2021-03-25 | 2022-01-04 |
| Regional Anesthesia for Totally Awake Upper Limb Surgery in PEDiatric Population local anaesthetic injection - Surgery, Anesthesia, Local | Phase 4 | Completed | GCS Ramsay Santé pour l'Enseignement et la Recherche | 100 | 2020-10-14 | 2026-07-16 |
| Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia RASBURICASE SR29142 - Lymphoma | Phase 4 | Completed | Sanofi | 50 | 2020-05-14 | 2022-04-25 |
| Safety and Efficacy of Miglustat in Chinese NPC Patients Miglustat - Niemann-Pick Disease, Type C | Phase 4 | Completed | Actelion | 17 | 2020-04-02 | 2025-03-30 |
| Ultrasound-guided Paravertebral Block Versus Mid-point Transverse Process Pleura Block in Mastectomy Surgery bupivacaine, 22 gauge 100 mm needle, Propofol - Mastectomy; Lymphedema, Anesthesia, Local | Phase 4 | Completed | Ataturk University | 64 | 2020-03-26 | 2022-04-18 |
| A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) Ibrutinib - Waldenstrom Macroglobulinemia | Phase 4 | Completed | Janssen Research & Development, LLC | 17 | 2019-12-18 | 2025-05-25 |
| A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis Secukinumab - Psoriasis | Phase 4 | Completed | Saakshi Khattri | 20 | 2019-12-02 | 2022-04-11 |
| SUBLOCADE Rapid Initiation Extension Study Sublocade - Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate | Phase 4 | Completed | Indivior Inc. | 17 | 2019-10-21 | 2025-03-25 |
| A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients inotuzumab ozogamicin-dose level 2, Inotuzumab ozogamicin-dose level 1 - Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma | Phase 4 | Completed | Pfizer | 102 | 2019-07-01 | 2023-11-22 |
Showing 20 of 131. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (30) · Lymphoma, Follicular (19) · Lymphoma (16) · Lymphoma, Non-Hodgkin (16) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Lymphedema (8) · Recurrence (8) · Lymphoma, T-Cell, Cutaneous (7) · Leukemia (6) · Asthma (5) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Mantle-Cell (5) · Sarcoidosis (5) · Waldenstrom Macroglobulinemia (5) · Elephantiasis, Filarial (4)
Hemic and Lymphatic Diseases (131) · Immune System Diseases (110) · Lymphoproliferative Disorders (110) · Immunoproliferative Disorders (102) · Neoplasms (102) · Neoplasms by Histologic Type (100) · Hematologic Diseases (49) · Lymphoma (47) · Leukemia, Lymphoid (38) · Leukemia (37) · Lymphoma, Non-Hodgkin (35) · Pathological Conditions, Signs and Symptoms (33) · Pathologic Processes (23) · Disease Attributes (15)
Cyclophosphamide (19) · Vincristine (16) · Cytarabine (15) · Methotrexate (14) · Dexamethasone (13) · Mercaptopurine (12) · Asparaginase (11) · Prednisolone (11) · Daunorubicin (10) · Doxorubicin (10) · Rituximab (10) · Prednisone (8) · Etoposide (7) · Granulocyte Colony-Stimulating Factor (7) · Teniposide (6)
PETHEMA Foundation (7) · Goethe University (5) · GlaxoSmithKline (4) · Institute of Hematology & Blood Diseases Hospital, China (4) · Eisai Inc. (3) · Hoffmann-La Roche (3) · Pfizer (3) · Sanofi (3) · Assistance Publique - Hôpitaux de Paris (2) · Biogen (2) · Children's Hospital of Michigan (2) · Depomed (2) · Genzyme, a Sanofi Company (2) · Green Cross Corporation (2) · Johann Wolfgang Goethe University Hospital (2)
United States (38) · China (20) · Germany (19) · Spain (16) · United Kingdom (10) · France (8) · Sweden (8) · Italy (7) · Poland (7) · Turkey (Türkiye) (7) · Austria (6) · Canada (6) · Czechia (6) · Russia (6) · South Korea (6)
Dieter Hoelzer, MD,PhD (4) · Shuhua Yi, Doc (4) · Bastida Pilar, Dr (2) · Dieter Hoelzer, MD, PhD (2) · Elyane Lombardy, M.D. (2) · A. Paz Coll, MD (1)
PMID 19144982, PMID 22442346, PMID 22493293, PMID 23024237, PMID 23770157, PMID 27561722, PMID 28751559, PMID 14752084, PMID 15014526, PMID 15158091, PMID 15257960, PMID 17223475, PMID 18165618, PMID 18263672, PMID 19564304, PMID 20118030, PMID 20560291, PMID 21575927, PMID 21828124, PMID 21890336, PMID 21932110, PMID 21940824, PMID 21987409, PMID 22198540, PMID 23574881, PMID 23775967, PMID 23775972, PMID 23938061, PMID 23981378, PMID 24752047, PMID 24824768, PMID 25253770, PMID 25359988, PMID 25693055, PMID 26001791, PMID 26359465, PMID 26377300, PMID 26691247, PMID 27165206, PMID 27852260, PMID 28597542, PMID 28664750, PMID 28969715, PMID 29420116, PMID 30333315, PMID 31644328, PMID 32067048, PMID 32113839, PMID 32158186, PMID 32550864
2009 (3), 2018 (1), 2019 (1), P30CA021765 (1), R01CA078957 (1), U01CA081445 (1)